Burning Rock Announces Results of 2025 Annual General Meeting

Rhea-AI Summary

Burning Rock (NASDAQ: BNR) announced that all shareholder resolutions at its 2025 annual general meeting held on Dec. 22, 2025 were duly passed.

Passed resolutions include: ratification of Ernst & Young Hua Ming LLP as auditor for the fiscal year ending Dec. 31, 2025 with directors authorized to set auditor remuneration; re-election of Feng Deng and Licen Lisa Xu as directors; and authorization for directors to take actions necessary to implement these resolutions.

Key Figures

AGM date December 22, 2025 Date 2025 annual general meeting was held

Fiscal year end December 31, 2025 Year-end for which Ernst & Young Hua Ming LLP was appointed auditor

Market Reality Check

$19.68 Last Close

Volume Volume 64,146 is at 0.85x the 20-day average of 75,777, indicating subdued trading activity versus typical levels. normal

Technical Price at 23.39 is trading above the 200-day MA of 7.72 and is close to the 52-week high of 23.59.

Peers on Argus 1 Up

Sector peers showed mixed moves, with names like PRE and MDXH up while FONR was down. Momentum scanner only flagged PSNL, up 4.01% without news, suggesting BNR’s 7.79% gain was more stock-specific than a broad diagnostics move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 01	AGM announcement	Neutral	-12.0%	Scheduled 2025 AGM with proposals on auditor and director elections.
Nov 20	Q3 2025 earnings	Positive	-3.1%	Q3 revenue growth, margin improvement, and narrowed net loss.
Sep 24	CDx approval Japan	Positive	-0.8%	MHLW approval of OncoScreen Plus CDx for capivasertib in breast cancer.
Sep 08	Q2 2025 earnings	Positive	+9.2%	Q2 revenue growth, higher gross margin, sharply reduced net loss.

Pattern Detected

Recent news often saw negative or muted reactions, including declines after a prior AGM announcement and positive clinical and earnings updates, with one strong gain on Q2 2025 results indicating inconsistent response to fundamentally positive developments.

Recent Company History

Over the last few months, Burning Rock reported multiple financial and operational updates. Q2 and Q3 2025 results showed revenue growth, margin improvement, and narrowed net losses, while a Japan MHLW approval for the OncoGuide OncoScreen Plus CDx marked a key regulatory milestone. The announcement of the 2025 AGM on December 23, 2025 previously coincided with a notable share price decline. Today’s AGM results confirm those agenda items were approved, formalizing decisions previously outlined.

Market Pulse Summary

The stock moved +7.8% in the session following this news. A strong positive reaction aligns with the stock trading near its 52-week high and well above the 200-day MA. Historically, Burning Rock’s news flow produced mixed reactions, with some positive clinical and earnings updates followed by declines and one notable gain after Q2 2025 results. Routine AGM approvals typically offer limited fundamental change, so sustainability of a sharp move would depend on broader sentiment and prior momentum rather than this governance update alone.

Key Terms

next generation sequencing medical

"a company focusing on the application of next generation sequencing (NGS) technology"

A collection of advanced laboratory methods that read and map large amounts of DNA or RNA quickly and at lower cost than older techniques; think of it as scanning thousands of pages of a book at once instead of reading one page at a time. Investors care because it accelerates drug development, enables precise diagnostics and personalized treatments, and can create recurring revenue from tests, instruments, and data services as adoption expands.

precision oncology medical

"NGS) technology in the field of precision oncology, today announced that all shareholder"

Precision oncology uses detailed biological information from a patient’s tumor—like genetic changes or specific markers—to choose treatments most likely to work for that individual, much like tailoring a suit to a person’s measurements instead of selling one-size-fits-all clothing. It matters to investors because these targeted approaches can improve treatment success, support premium pricing and companion diagnostic tests, and shorten development and approval timelines, creating focused markets with both higher potential returns and specialized risks.

AI-generated analysis. Not financial advice.

GUANGZHOU, China, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company’s 2025 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions:

1. as an ordinary resolution, THAT the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2025 be ratified and that the directors of the Company be authorized to determine the remuneration of the auditor;
   
2. as an ordinary resolution, THAT Feng Deng and Licen Lisa Xu be re-elected as directors of the Company; and
   
3. as an ordinary resolution, THAT each of the directors of the Company be authorized to take any and all action that might be necessary to effect the foregoing resolutions as such director, in his or her absolute discretion, thinks fit.
   
   

About Burning Rock

Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.

For more information about Burning Rock, please visit: ir.brbiotech.com.

Contact: IR@brbiotech.com

FAQ

What resolutions did Burning Rock (BNR) pass at the Dec. 22, 2025 annual general meeting?

Shareholders ratified Ernst & Young Hua Ming LLP as auditor for fiscal 2025, re-elected Feng Deng and Licen Lisa Xu, and authorized directors to implement the resolutions.

Who is Burning Rock's auditor for the fiscal year ending Dec. 31, 2025 (BNR)?

Ernst & Young Hua Ming LLP was ratified as auditor for the fiscal year ending Dec. 31, 2025.

Which directors were re-elected at Burning Rock's 2025 AGM (BNR)?

Feng Deng and Licen Lisa Xu were re-elected as directors at the Dec. 22, 2025 meeting.

When did Burning Rock hold its 2025 annual general meeting (BNR)?

The annual general meeting was held on Dec. 22, 2025.

Did Burning Rock authorize directors to set auditor remuneration (BNR)?

Yes. Shareholders authorized the directors to determine the remuneration of the auditor.